Switch theme
Sign up to access all valuation multiples
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
1955
1.4K+
LTM Revenue $158M
LTM EBITDA $36.0M
$351M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Antibiotice has a last 12-month revenue (LTM) of $158M and a last 12-month EBITDA of $36.0M.
In the most recent fiscal year, Antibiotice achieved revenue of $150M and an EBITDA of $34.0M.
Antibiotice expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Antibiotice valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $158M | XXX | $150M | XXX | XXX | XXX |
| Gross Profit | $104M | XXX | $101M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $36.0M | XXX | $34.0M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $26.3M | XXX | $23.2M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $21.8M | XXX | $22.8M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $30.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Antibiotice's stock price is RON 2 (or $0).
Antibiotice has current market cap of RON 1.4B (or $311M), and EV of RON 1.6B (or $351M).
See Antibiotice trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $351M | $311M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Antibiotice has market cap of $311M and EV of $351M.
Antibiotice's trades at 2.3x EV/Revenue multiple, and 10.3x EV/EBITDA.
Equity research analysts estimate Antibiotice's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Antibiotice has a P/E ratio of 14.3x.
See valuation multiples for Antibiotice and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $311M | XXX | $311M | XXX | XXX | XXX |
| EV (current) | $351M | XXX | $351M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 9.8x | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 15.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.3x | XXX | 13.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -75.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAntibiotice's last 12 month revenue growth is 12%
Antibiotice's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Antibiotice's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Antibiotice's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Antibiotice and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Antibiotice acquired XXX companies to date.
Last acquisition by Antibiotice was XXXXXXXX, XXXXX XXXXX XXXXXX . Antibiotice acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Antibiotice founded? | Antibiotice was founded in 1955. |
| Where is Antibiotice headquartered? | Antibiotice is headquartered in Romania. |
| How many employees does Antibiotice have? | As of today, Antibiotice has 1.4K+ employees. |
| Is Antibiotice publicy listed? | Yes, Antibiotice is a public company listed on BSE. |
| What is the stock symbol of Antibiotice? | Antibiotice trades under ATB ticker. |
| When did Antibiotice go public? | Antibiotice went public in 1997. |
| Who are competitors of Antibiotice? | Similar companies to Antibiotice include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Antibiotice? | Antibiotice's current market cap is $311M |
| What is the current revenue of Antibiotice? | Antibiotice's last 12 months revenue is $158M. |
| What is the current revenue growth of Antibiotice? | Antibiotice revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Antibiotice? | Current revenue multiple of Antibiotice is 2.2x. |
| Is Antibiotice profitable? | Yes, Antibiotice is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Antibiotice? | Antibiotice's last 12 months EBITDA is $36.0M. |
| What is Antibiotice's EBITDA margin? | Antibiotice's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Antibiotice? | Current EBITDA multiple of Antibiotice is 9.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
